Sanofi and Regeneron eye younger patients for Dupixent amid rising tide of rivals in atopic dermatitis
With a suite of rivals turning up the heat in atopic dermatitis, Sanofi and Regeneron are looking to keep their competitive edge with a label …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
